Zymeworks' BLA for zanidatamab in second-line biliary tract cancer treatment accepted by China NMPA, US FDA BLA for priority review.
Zymeworks announced the China NMPA's acceptance of a Biologics License Application (BLA) for zanidatamab for a second-line treatment of biliary tract cancer. The U.S. FDA's BLA for the same drug has also been accepted for Priority Review. Zymeworks is entitled to receive an $8M milestone payment from BeiGene, and up to $164M based on additional milestones and royalties on product sales.
June 10, 2024
4 Articles